Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.74 |
| ▸ | CES1 | P23141 | 4/20 | 0.74 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.74 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.70 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1649013 | 1.00 | CES2 (0.74) | CES2CES1ALOX5PTPN1PTPN2 | |
| SCHEMBL1649012 | 1.00 | CES2 (0.74) | CES2CES1ALOX5PTPN1PTPN2 | |
| SCHEMBL1721910 | 0.91 | PTPN1 (0.63) | CES2CES1ALOX5PTPN1PTPN2 | |
| SCHEMBL1721289 | 0.89 | PTPN1 (0.61) | CES2CES1ALOX5PTPN1PTPN2 | |
| SCHEMBL974587 | 0.86 | PTPN1 (0.73) | CES2CES1ALOX5PTPN1PTPN2 | |
| SCHEMBL974588 | 0.86 | PTPN1 (0.73) | CES2CES1ALOX5PTPN1PTPN2 | |
| SCHEMBL31593848 | 0.86 | PTPN1 (0.73) | CES2CES1ALOX5PTPN1PTPN2 | |
| SCHEMBL6913431 | 0.86 | PTPN1 (0.73) | CES2CES1ALOX5PTPN1PTPN2 | |
| Katonic Acid SCHEMBL13144259 | 0.85 | CES1 (1.00) | CES2CES1ALOX5PTPN1PTPN2 | |
| Katonic Acid SCHEMBL14071724 | 0.85 | CES1 (1.00) | CES2CES1ALOX5PTPN1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220296544-A1 | NANOEMULSION OF 18BETA-GLYCYRRHETINIC ACID | PROYECTOS ATSO S.A.P.I. DE C.V. (MX) | 2022-09-22 | — | — | US | disclosed |
| EP-4023219-A1 | NANOEMULSION OF 18BETA-GLYCYRRHETINIC ACID | Atso Corporate Affairs, S.A. De C.V. (MX) | 2022-07-06 | — | — | EP | disclosed |
| CN-114450001-A | 18 beta-glycyrrhetinic acid nano emulsion | 亚索事务公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021025550-A1 | NANOEMULSION OF 18β-GLYCYRRHETINIC ACID | ATSO CORPORATE AFFAIRS, S.A. DE C.V. (MX) | 2021-02-11 | — | — | WO | disclosed |
| US-20190302069-A1 | APPARATUS AND METHOD FOR CLASSIFYING A TOBACCO SAMPLE INTO ONE OF A PREDEFINED SET OF TASTE CATEGORIES | BRITISH AMERICAN TOBACCO (INVESTMENTS) LIMITED (GB) | 2019-10-03 | — | — | US | disclosed |
| EP-3478094-A1 | APPARATUS AND METHOD FOR CLASSIFYING A TOBACCO SAMPLE INTO ONE OF A PREDEFINED SET OF TASTE CATEGORIES | British American Tobacco (Investments) Limited (GB) | 2019-05-08 | — | — | EP | disclosed |
| WO-2018007789-A1 | APPARATUS AND METHOD FOR CLASSIFYING A TOBACCO SAMPLE INTO ONE OF A PREDEFINED SET OF TASTE CATEGORIES | BRITISH AMERICAN TOBACCO (INVESTMENTS) LIMITED (GB) | 2018-01-11 | — | — | WO | disclosed |
| US-20110020226-A1 | PARTICLE STRUCTURES COMPRISING STEROLS AND SAPONINS | NORDIC VACCINE TECHNOLOGY A/S | 2011-01-27 | — | — | US | disclosed |
| EP-1409009-A1 | THERAPEUTICAL VACCINATION | Nordic Vaccine Technology A/S (DK) | 2004-04-21 | — | — | EP | disclosed |
| EP-1377320-A2 | POLYNUCLEOTIDE BINDING COMPLEXES COMPRISING STEROLS AND SAPONINS | Nordic Vaccine Technology A/S (DK) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002102407-A1 | THERAPEUTICAL VACCINATION | NORDIC VACCINE TECHNOLOGY A/S (DK) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002080981-A2 | POLYNUCLEOTIDE BINDING COMPLEXES COMPRISING STEROLS AND SAPONINS | NORDIC VACCINE TECHNOLOGY A/S (DK) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020226-A1 | PARTICLE STRUCTURES COMPRISING STEROLS AND SAPONINS | LSS, SNRPE, HLA-C | CES2 2103/4885CES1 641/4885ALOX5 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.